Evaluating the response to neoadjuvant treatment in stage IIIA lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the pathological response in patients with resectable stage IIIA non-small cell lung cancer (NSCLC) after receiving neoadjuvant treatment. It will utilize data collected from the Tumor Thoracic Registry and clinical trial case report forms without interfering in standard clinical practices. The study will involve re-evaluating specimens from approximately 150 patients across multiple Spanish sites to determine the correlation between pathological response and overall survival as well as disease-free survival.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with resectable stage IIIA disease (according to American Joint Committee on Cancer \[AJCC\] lung cancer edition 7 or 8) who were included in the Tumor Thoracic Registry data base and in stage IIIA clinical trials which the sponsor is Fundación GECP.
* Patients with histologically N2 involvement confirmed
* Patients diagnosed as stage IIIA from 2010 and 2017
* Patients who have received neoadjuvant platinum-based treatment and surgery
* Age ≥ 18 years at time of study entry
* PET /TC at diagnosis

Exclusion Criteria:

* Patients who received chemoradiotherapy neoadjuvant treatment
* Patients who were not resected after neoadjuvant treatment
* Patients who were diagnosed after June 2017

Where it's running

• Hospital Universitario De A Coruna
  A Coruña, A Coruña, Spain Recruiting
• Hospital General Universitario de Alicante
  Alicante, Alicante, Spain Recruiting
• ICO Badalona, Hospital Germans Trias i Pujol
  Badalona, Barcelona, Spain Recruiting
• Hospital Vall d'Hebron
  Barcelona, Barcelona, Spain Recruiting
• Hospital de la Santa Creu i Sant Pau
  Barcelona, Barcelona, Spain Recruiting
• ICO Hospitalet
  L'Hospitalet de Llobregat, Barcelona, Spain Recruiting

Study contacts

• Study coordinator: Eva Pereira
• Email: gecp@gecp.org
• Phone: +34934302006

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining local therapy and durvalumab for advanced lung cancer after initial treatment

  This study is testing whether combining local treatments like surgery or radiation with the immunotherapy durvalumab can help people with advanced lung cancer live longer and feel better after their initial treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04892953

• BL-B01D1 plus osimertinib vs osimertinib alone in unresectable EGFR-mutated NSCLC (Stage III) after chemoradiation

  This trial tests whether adding BL-B01D1 to osimertinib helps people with unresectable Stage III EGFR-mutated non-small cell lung cancer who did not progress after platinum-based chemoradiation.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07640789

• Pulmonary rehabilitation for people who survived advanced non-small cell lung cancer

  This research will try an eight-week pulmonary rehabilitation program to see if it helps people with advanced non-small cell lung cancer breathe easier and have more energy.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07104630

• Chemoradiotherapy followed by durvalumab for stage III lung cancer

  This study is testing if giving a combination of chemotherapy, radiation, and the immunotherapy durvalumab can help people with stage III lung cancer who couldn't initially have surgery, to see if it improves their chances of survival.

  Recruiting Phase 4 Amsterdam UMC, location VUmc · Amsterdam · NCT06908070

• Examining immune responses in advanced lung cancer patients after treatment

  This study looks at how the immune system responds in patients with advanced lung cancer after they receive a combination of chemotherapy, radiation, and immunotherapy to see how these treatments work together.

  Recruiting at 22 sites Fundación GECP · Ferrol, A Coruña and 21 other locations · NCT06634199

• New treatment for advanced non-small-cell lung cancer using a virus and chemotherapy

  This study is testing a new treatment that combines a special virus and chemotherapy to see if it can help people with advanced lung cancer who haven't responded to previous treatments.

  Recruiting at 15 sites Phase 2 Genelux Corporation · Bullhead City, Arizona and 14 other locations · NCT06463665

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.